Who are NewAmsterdam Pharma Company N.V.'s main suppliers?

NewAmsterdam Pharma Company N.V. (NAMS) key suppliers include: A-MENARINI-INTERNATIONAL-LICENSING-S-A, Merck & Co., Inc., NAMSW. View the full supplier network at chainsifter.com/chain/NAMS.

Who are NewAmsterdam Pharma Company N.V.'s major customers?

NewAmsterdam Pharma Company N.V. (NAMS) key customers include: MENARINI, Merck & Co., Inc., NAMSW, FRAZIER-LIFE-SCIENCES-ACQUISITION-CORPORATION, GR8-PEOPLE-INC and 3 more. View the full customer network at chainsifter.com/chain/NAMS.

What sector is NewAmsterdam Pharma Company N.V. in?

NewAmsterdam Pharma Company N.V. (NAMS) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

NewAmsterdam Pharma Company N.V. Suppliers, Customers & Supply Chain (NAMS)

3Suppliers

8Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

NewAmsterdam Pharma Company N.V. (NAMS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

15Total relationships

2Distinct source URLs

6High confidence

0.761Average confidence

2026-10-29Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

NewAmsterdam Pharma Company N.V. Suppliers

Ticker	Name	Confidence	Evidence
A-MENARINI-INTERNATIONAL-LICENSING-S-A	A-MENARINI-INTERNATIONAL-LICENSING-S-A	92%	NewAmsterdam Pharma B.V. entered into a supply agreement with A. Menarini International Licensing S.A. ("Menarini") to provide commercial supply of Products (as defined below) for distribution in spe…
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from NAMS graph: Reciprocal relationship from MRK graph: Reciprocal relationship from NAMS graph: Reciprocal relationship from MRK grap…
NAMSW	NAMSW	72%	Reciprocal relationship from NAMSW graph: Reciprocal relationship from NAMS graph: Reciprocal relationship from NAMSW graph: exercise of warrants — See notes to consolidated financial statements 10 N…

NewAmsterdam Pharma Company N.V. Customers

Ticker	Name	Confidence	Evidence
MENARINI	MENARINI	92%	In addition, Menarini is expected to purchase obicetrapib and obicetrapib and ezetimibe FDC tablets from us in accordance with a supply agreement to be entered into by Menarini and us
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from NAMS graph: Reciprocal relationship from MRK graph: Reciprocal relationship from NAMS graph: Reciprocal relationship from MRK grap…
NAMSW	NAMSW	72%	Reciprocal relationship from NAMSW graph: Combination Agreement) for each of NewAmsterdam Pharma’s BROADWAY clinical trial and BROOKLYN clinical trial at any time during the period beginning on the C…
FRAZIER-LIFE-SCIENCES-ACQUISITION-CORPORATION	FRAZIER-LIFE-SCIENCES-ACQUISITION-CORPORATION	62%	ntities under common control. NewAmsterdam Pharma Holding B.V. and Frazier Life Sciences Acquisition Corporation had no material operations, and the mergers had no impact on the consolidated financia…
GR8-PEOPLE-INC	GR8-PEOPLE-INC	62%	ntly impacts our ability to generate revenue. At the end of each reporting period, we assess the probability of significant reversals for any amounts that become likely to be realized prior to recogn…
MITSUBISHI-TANABE-PHARMA-CORPORATION	MITSUBISHI-TANABE-PHARMA-CORPORATION	62%	-how of the patented drug Obicetrapib and the in-process research and development (“IPR&D”). The Company paid consideration of € 1 for the IPR&D asset and could potentially make an additional conting…
RENAISSANCE-AVENTURA-LLC	RENAISSANCE-AVENTURA-LLC	62%	ntly impacts our ability to generate revenue. At the end of each reporting period, we assess the probability of significant reversals for any amounts that become likely to be realized prior to recogn…
USA-LLC	USA-LLC	62%	, control of the product is transferred upon the conveyance of title, which occurs when the product is made available to the customer. The transaction price is contractually fixed at a markup to the …

NewAmsterdam Pharma Company N.V. Debt Obligations

Instrument	Description	Confidence	Evidence
NAMS-DEBT	Debt stack $202,000	90%	Market cache reports total debt of $202,000.
NAMS-DEBT-11162	Warrants outstanding: 1638000	90%	xbrl warrant detail from xbrl 2025-12-31.
NAMS-DEBT-11163	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2021-12-31.

NewAmsterdam Pharma Company N.V. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for NewAmsterdam Pharma Company N.V..

NewAmsterdam Pharma Company N.V. Ownership

Holder	Name	Confidence	Evidence
NAMS-OWNER-FRAZIER-LIFE-SCIENCES-MANAGEMENT	Frazier Life Sciences Management, L.P.	90%	13F overlay lists Frazier Life Sciences Management, L.P. as top holder; 173 tracked holders.

NewAmsterdam Pharma Company N.V. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
NAMSW	NewAmsterdam Pharma Co N.V.	100.00	1	['customer', 'supplier']
MRK	Merck & Co., Inc.	100.00	1	['customer', 'supplier']
DKS	DICK'S Sporting Goods, Inc.	50.00	2
IMMP	Immutep Limited	50.00	2
CYTK	Cytokinetics, Incorporated	50.00	2
CBIH	Cannabis Bioscience International Holdings, Inc.	50.00	2
EDSA	Edesa Biotech, Inc.	50.00	2
EVFM	Evofem Biosciences, Inc.	50.00	2
CORT	Corcept Therapeutics Incorporated	50.00	2
CHRS	Coherus Oncology, Inc.	50.00	2
DYN	Dyne Therapeutics, Inc.	50.00	2
CTMX	CytomX Therapeutics, Inc.	50.00	2
GYRE	Gyre Therapeutics, Inc.	50.00	2
REGN	Regeneron Pharmaceuticals, Inc.	50.00	2
BBVA	Banco Bilbao Vizcaya Argentaria, S.A.	50.00	2
AZN	AstraZeneca PLC	50.00	2
ADAG	Adagene Inc.	50.00	2
ORANY	ORANGE	50.00	2
AVIR	Atea Pharmaceuticals, Inc.	50.00	2
BNBX	BNB Plus Corp.	50.00	2

NewAmsterdam Pharma Company N.V. Supply Chain